Show simple item record

dc.contributor.authorFrancis, PA
dc.contributor.authorPagani, O
dc.contributor.authorFleming, GF
dc.contributor.authorWalley, BA
dc.contributor.authorColleoni, M
dc.contributor.authorLáng, I
dc.contributor.authorGómez, HL
dc.contributor.authorTondini, C
dc.contributor.authorCiruelos, E
dc.contributor.authorBurstein, HJ
dc.contributor.authorBonnefoi, HR
dc.contributor.authorBellet, M
dc.contributor.authorMartino, S
dc.contributor.authorGeyer, CE
dc.contributor.authorGoetz, MP
dc.contributor.authorStearns, V
dc.contributor.authorPinotti, G
dc.contributor.authorPuglisi, F
dc.contributor.authorSpazzapan, S
dc.contributor.authorCliment, MA
dc.contributor.authorPavesi, L
dc.contributor.authorRuhstaller, T
dc.contributor.authorDavidson, NE
dc.contributor.authorColeman, R
dc.contributor.authorDebled, M
dc.contributor.authorBuchholz, S
dc.contributor.authorIngle, JN
dc.contributor.authorWiner, EP
dc.contributor.authorMaibach, R
dc.contributor.authorRabaglio-Poretti, M
dc.contributor.authorRuepp, B
dc.contributor.authorDi Leo, A
dc.contributor.authorCoates, AS
dc.contributor.authorGelber, RD
dc.contributor.authorGoldhirsch, A
dc.contributor.authorRegan, MM
dc.contributor.authorSOFT and TEXT Investigators and the International Breast Cancer Study Group
dc.date.accessioned2021-07-02T10:58:16Z
dc.date.available2021-07-02T10:58:16Z
dc.identifier.citationThe New England journal of medicine, 2018, 379 (2), pp. 122 - 137
dc.identifier.issn0028-4793
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4664
dc.identifier.eissn1533-4406
dc.identifier.doi10.1056/nejmoa1803164
dc.description.abstractBackground In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials.Methods Premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in TEXT. Randomization was stratified according to the receipt of chemotherapy.Results In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression, and 85.9% with exemestane plus ovarian suppression (P=0.009 for tamoxifen alone vs. tamoxifen plus ovarian suppression). The 8-year rate of overall survival was 91.5% with tamoxifen alone, 93.3% with tamoxifen plus ovarian suppression, and 92.1% with exemestane plus ovarian suppression (P=0.01 for tamoxifen alone vs. tamoxifen plus ovarian suppression); among the women who remained premenopausal after chemotherapy, the rates were 85.1%, 89.4%, and 87.2%, respectively. Among the women with cancers that were negative for HER2 who received chemotherapy, the 8-year rate of distant recurrence with exemestane plus ovarian suppression was lower than the rate with tamoxifen plus ovarian suppression (by 7.0 percentage points in SOFT and by 5.0 percentage points in TEXT). Grade 3 or higher adverse events were reported in 24.6% of the tamoxifen-alone group, 31.0% of the tamoxifen-ovarian suppression group, and 32.3% of the exemestane-ovarian suppression group.Conclusions Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence. The frequency of adverse events was higher in the two groups that received ovarian suppression than in the tamoxifen-alone group. (Funded by Pfizer and others; SOFT and TEXT ClinicalTrials.gov numbers, NCT00066690 and NCT00066703 , respectively.).
dc.formatPrint-Electronic
dc.format.extent122 - 137
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectSOFT and TEXT Investigators and the International Breast Cancer Study Group
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectTamoxifen
dc.subjectAndrostadienes
dc.subjectReceptor, erbB-2
dc.subjectAntineoplastic Agents, Hormonal
dc.subjectAromatase Inhibitors
dc.subjectDisease-Free Survival
dc.subjectChemotherapy, Adjuvant
dc.subjectFollow-Up Studies
dc.subjectPremenopause
dc.subjectAdult
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectYoung Adult
dc.subjectKaplan-Meier Estimate
dc.titleTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
dc.typeJournal Article
dcterms.dateAccepted2018-06-01
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1056/nejmoa1803164
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe New England journal of medicine
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished
pubs.volume379
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamClinical Trials & Statistics Uniten_US
dc.contributor.icrauthorBliss, Judithen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record